Total Payments
$4,722
2022 Payments
$15.01
Companies
15
Transactions
69
Medicare Patients
397
Medicare Billing
$114,238
Payment Breakdown by Category
Food & Beverage$2,299 (48.7%)
Research$2,260 (47.9%)
Education$163.54 (3.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,299 | 65 | 48.7% |
| Unspecified | $2,260 | 1 | 47.9% |
| Education | $163.54 | 3 | 3.5% |
Payments by Type
General
$2,463
68 transactions
Research
$2,260
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Indivior Inc. | $2,260 | 1 | $0 (2018) |
| Otsuka America Pharmaceutical, Inc. | $677.68 | 9 | $0 (2020) |
| Alkermes, Inc. | $368.84 | 6 | $0 (2022) |
| Allergan Inc. | $362.92 | 17 | $0 (2019) |
| Janssen Pharmaceuticals, Inc | $232.52 | 4 | $0 (2019) |
| Teva Pharmaceuticals USA, Inc. | $133.30 | 3 | $0 (2019) |
| Lundbeck LLC | $124.41 | 7 | $0 (2018) |
| ACADIA Pharmaceuticals Inc | $114.36 | 1 | $0 (2017) |
| Tris Pharma Inc | $101.85 | 7 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $99.00 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $15.01 | 1 | Alkermes, Inc. ($15.01) |
| 2020 | $131.50 | 2 | Otsuka America Pharmaceutical, Inc. ($107.39) |
| 2019 | $371.05 | 9 | Teva Pharmaceuticals USA, Inc. ($121.78) |
| 2018 | $2,914 | 22 | Indivior Inc. ($2,260) |
| 2017 | $1,291 | 35 | Otsuka America Pharmaceutical, Inc. ($314.01) |
All Payment Transactions
69 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/16/2022 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $15.01 | General |
| Category: CNS | ||||||
| 02/19/2020 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $107.39 | General |
| Category: PSYCHIATRY | ||||||
| 01/31/2020 | Sunovion Pharmaceuticals Inc. | LATUDA (Drug) | Food and Beverage | In-kind items and services | $24.11 | General |
| Category: CNS | ||||||
| 11/05/2019 | Allergan Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $12.80 | General |
| Category: NEUROSCIENCE | ||||||
| 09/26/2019 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $20.79 | General |
| Category: Neuroscience | ||||||
| 05/16/2019 | Allergan Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.71 | General |
| Category: NEUROSCIENCE | ||||||
| 03/23/2019 | Teva Pharmaceuticals USA, Inc. | AUSTEDO (Drug) | Food and Beverage | In-kind items and services | $120.18 | General |
| Category: Central Nervous System | ||||||
| 03/22/2019 | Teva Pharmaceuticals USA, Inc. | AUSTEDO (Drug) | Food and Beverage | In-kind items and services | $1.60 | General |
| Category: Central Nervous System | ||||||
| 03/05/2019 | Novo Nordisk Inc | — | Education | In-kind items and services | $32.27 | General |
| 03/05/2019 | Novo Nordisk Inc | — | Education | In-kind items and services | $32.27 | General |
| 01/15/2019 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $120.18 | General |
| Category: PSYCHIATRY | ||||||
| 01/15/2019 | Allergan Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $16.25 | General |
| Category: NEUROSCIENCE | ||||||
| 08/30/2018 | Allergan Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $4.33 | General |
| Category: NEUROSCIENCE | ||||||
| 08/29/2018 | Allergan Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $105.83 | General |
| Category: NEUROSCIENCE | ||||||
| 08/24/2018 | Otsuka America Pharmaceutical, Inc. | ABILIFY MAINTENA (Drug) | Food and Beverage | In-kind items and services | $11.88 | General |
| Category: PSYCHIATRY | ||||||
| 08/24/2018 | Otsuka America Pharmaceutical, Inc. | ABILIFY MAINTENA (Drug) | Food and Beverage | In-kind items and services | $8.65 | General |
| Category: PSYCHIATRY | ||||||
| 08/13/2018 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $18.21 | General |
| Category: PSYCHIATRY | ||||||
| 08/08/2018 | Allergan Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $16.74 | General |
| Category: NEUROSCIENCE | ||||||
| 08/02/2018 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $20.70 | General |
| Category: PSYCHIATRY | ||||||
| 07/25/2018 | Allergan Inc. | VIBERZI (Drug) | Food and Beverage | In-kind items and services | $16.74 | General |
| Category: GASTROENTEROLOGY | ||||||
| 06/14/2018 | Tris Pharma Inc | Dyanavel XR (Drug) | Food and Beverage | In-kind items and services | $13.15 | General |
| Category: ADHD | ||||||
| 05/30/2018 | Alkermes, Inc. | — | Food and Beverage | In-kind items and services | $94.98 | General |
| 05/16/2018 | Tris Pharma Inc | Dyanavel XR (Drug) | Food and Beverage | In-kind items and services | $14.62 | General |
| Category: ADHD | ||||||
| 05/15/2018 | Lundbeck LLC | TRINTELLIX (Drug) | Food and Beverage | Cash or cash equivalent | $15.75 | General |
| Category: PSYCHIATRY | ||||||
| 04/25/2018 | Tris Pharma Inc | Dyanavel XR (Drug) | Food and Beverage | In-kind items and services | $15.22 | General |
| Category: ADHD | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| An Open-Label, Depot Buprenorphine RBP-6000 Treatment Extension Study in Subjects With Opioid Use Disorder | Indivior Inc. | $2,260 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 1 | 11 | 22 | $5,500 | $1,898 |
| 2021 | 4 | 163 | 532 | $119,700 | $55,373 |
| 2020 | 5 | 223 | 587 | $141,950 | $56,967 |
Total Patients
397
Total Services
1,141
Medicare Billing
$114,238
Procedure Codes
10
All Medicare Procedures & Services
10 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 11 | 22 | $5,500 | $1,898 | 34.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 73 | 271 | $67,750 | $28,294 | 41.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 24 | 96 | $24,000 | $14,928 | 62.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 52 | 101 | $15,150 | $6,849 | 45.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 14 | 64 | $12,800 | $5,302 | 41.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 97 | 352 | $88,000 | $31,287 | 35.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 46 | 124 | $31,000 | $15,092 | 48.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 22 | 26 | $9,100 | $4,625 | 50.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 46 | 63 | $9,450 | $3,953 | 41.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 12 | 22 | $4,400 | $2,010 | 45.7% |
About Dr. Scott Segal, MD
Dr. Scott Segal, MD is a Addiction Medicine healthcare provider based in North Miami, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/10/2005. The National Provider Identifier (NPI) number assigned to this provider is 1821086323.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Scott Segal, MD has received a total of $4,722 in payments from pharmaceutical and medical device companies, with $15.01 received in 2022. These payments were reported across 69 transactions from 15 companies. The most common payment nature is "Food and Beverage" ($2,299).
As a Medicare-enrolled provider, Segal has provided services to 397 Medicare beneficiaries, totaling 1,141 services with total Medicare billing of $114,238. Data is available for 3 years (2020–2022), covering 10 distinct procedure/service records.
Ad
Practice Information
- Specialty Addiction Medicine
- Other Specialties Addiction Medicine, Psychiatry
- Location North Miami, FL
- Active Since 10/10/2005
- Last Updated 01/16/2024
- Taxonomy Code 2084A0401X
- Entity Type Individual
- NPI Number 1821086323
Products in Payments
- SUBLOCADE (Drug) $2,260
- REXULTI (Drug) $751.10
- VRAYLAR (Drug) $346.18
- INVEGA SUSTENNA (Drug) $211.73
- Aristada 441 mg (Drug) $135.37
- AUSTEDO (Drug) $121.78
- NUPLAZID (Drug) $114.36
- Dyanavel XR (Drug) $101.85
- LATUDA (Drug) $55.41
- MYDAYIS (Drug) $53.56
- ABILIFY MAINTENA (Drug) $35.24
- NeuroStar TMS Therapy (Device) $23.81
- VYVANSE (Drug) $22.66
- SPRAVATO (Drug) $20.79
- VIBERZI (Drug) $16.74
- TRINTELLIX (Drug) $15.75
- ARISTADA (Drug) $15.01
- ARESTIN (Drug) $14.63
- CYCLOSET (Drug) $13.08
- SD809-TD (Drug) $11.52
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.